Logo

Novo Nordisk's Esperoct (turoctocog alfa pegol- N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A

Share this

Novo Nordisk's Esperoct (turoctocog alfa pegol- N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A

Shots:

  • The approval is based on results from pre-registration clinical programme assessing Esperoct in 270 patients with severe hemophilia A with 5+years of clinical exposure. The authorization covers all 28 European Union member states
  • The marketing authorization follows EMA’s CHMP positive opinion granted on Apr 26- 2019 with its expected launch in European countries in H2’19
  • Esperoct is an extended half-life factor VIII molecule providing 1.6fold half-life prolongation- indicated for the prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (≥12yrs.) and adults with hemophilia A

Ref: Novo Nordisk | Image: IVSA

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions